Journal
CANCER RESEARCH
Volume 68, Issue 16, Pages 6652-6660Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-1468
Keywords
-
Categories
Funding
- NIH-National Cancer Institute Center for Cancer Nanotechnology Excellence Focused on Therapeutic Response at Stanford
- Stanford Bio-X Initiative
- NIH-National Cancer Institute [CA135109-01]
- Stanford Graduate
Ask authors/readers for more resources
Chemically functionalized single-walled carbon nanotubes (SWNT) have shown promise in tumor-targeted accumulation in mice and exhibit biocompatibility, excretion, and little toxicity. Here, we show in vivo SWNT drug delivery for tumor suppression in mice. We conjugate paclitaxel (PTX), a widely used cancer chemotherapy drug, to branched polyethylene glycol chains on SWNTs via a cleavable ester bond to obtain a water-soluble SWNT-PTX conjugate. SWNT-PTX affords higher efficacy in suppressing tumor growth than clinical Taxol in a murine 4T1 breast cancer model, owing to prolonged blood circulation and 10-fold higher tumor PTX uptake by SWNT delivery likely through enhanced permeability and retention. Drug molecules carried into the reticuloendothelial. path-system are released from SWNTs and excreted via biliary way without causing obvious toxic effects to normal organs. Thus, nanotube drug delivery, is promising for high treatment efficacy and minimum side effects for future cancer therapy with low drug doses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available